Avastin bevacizumab regulatory update

The U.K.'s NICE issued a report that supports an appraisal of Avastin bevacizumab from Roche to treat wet age-related macular degeneration (AMD) and other eye conditions. The Department of Health will now decide whether or not to refer Avastin to NICE for a technology appraisal in the indication. NICE does not normally appraise drugs for off-label indications, but said that it would at the request of the Department of Health. ...